You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Unresectable or metastatic BRAF V600 mutant melanoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)

Completed
  • BRAF V600E Unresectable or Metastatic Melanoma
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jun 9, 2022

Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Recruiting
  • Melanoma (Skin)
  • +2 more
    • Evora, Portugal
      Hospital Evora
    May 30, 2022

    BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

    Active, not recruiting
    • BRAF V600E Mutation Present
    • +9 more
    • Boston, Massachusetts
    • +1 more
    Jun 28, 2022

    BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma Trial in Czechia, Italy, Spain (Encorafenib + Binimetinib)

    Not yet recruiting
    • BRAF V600 Mutation
    • +3 more
    • Encorafenib + Binimetinib
    • Olomouc, Czechia
    • +5 more
    Sep 14, 2021

    Malignant Melanoma Trial in Germany (Encorafenib, Binimetinib, Pembrolizumab)

    Completed
    • Malignant Melanoma
    • Freiburg, Baden-Württemberg, Germany
    • +10 more
    Feb 13, 2021

    Associated Factors, and Clinical Outcomes of Prescribing

    Completed
    • BRAF v600 Mutated Metastatic Melanoma
      • East Hanover, New Jersey
        Novartis Pharmaceuticals
      Mar 28, 2023

      Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)

      Recruiting
      • Metastatic Melanoma
      • BRAF Gene Mutation
      • Nilotinib 100mg
      • +5 more
      • Lexington, Kentucky
        Markey Cancer Center
      Jul 22, 2022

      Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

      Not yet recruiting
      • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
      • Non-investigational
      • (no location specified)
      May 11, 2023

      Melanoma, BRAF V600 Mutation, Unresectable Melanoma Trial in Rennes (Binimetinib Oral Tablet)

      Completed
      • Melanoma
      • +3 more
      • Binimetinib Oral Tablet
      • Rennes, France
        Biotrial
      Mar 31, 2023

      Colorectal Cancer Metastatic Trial (Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy

      Not yet recruiting
      • Colorectal Cancer Metastatic
      • Tunlametinib plus Vemurafenib
      • Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
      • (no location specified)
      Aug 15, 2023

      Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS

      Recruiting
      • Clinical Stage IV Cutaneous Melanoma AJCC v8
      • +3 more
      • Scottsdale, Arizona
      • +2 more
      Jan 4, 2023

      BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,

      Recruiting
      • BRAF NP_004324.2:p.V600M
      • +6 more
      • Portland, Oregon
        Providence Portland Medical Center
      Aug 17, 2022

      NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • +32 more
      • (no location specified)
      Mar 30, 2023

      BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer

      Recruiting
      • Metastatic Non-small Cell Lung Cancer
      • BRAF V600 Mutation
        • Lyon, Rhône Alpes, France
          CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Prad
        Sep 14, 2022

        Advanced Melanoma in Russian Experience

        Completed
        • Cutaneous Melanoma, Stage IV
        • BRAF V600 Mutation
          • Balashikha, Russian Federation
          • +10 more
          Sep 23, 2021

          Non-small-cell Lung Cancer Trial (HL-085+Vemurafenib)

          Not yet recruiting
          • Non-small-cell Lung Cancer
          • (no location specified)
          Jun 8, 2023

          Melanoma Trial in Sydney, Wollstonecraft, Melbourne (Dabrafenib, Trametinib, Pembrolizumab)

          Active, not recruiting
          • Melanoma
          • Sydney, New South Wales, Australia
          • +2 more
          Apr 4, 2022

          Primary Malignant Brain Tumor Trial in China (ABM-1310)

          Not yet recruiting
          • Primary Malignant Brain Tumor
          • Beijing, Beijing, China
          • +3 more
          May 28, 2023

          Malignant Melanoma, Brain Metastases Trial in Tucson (E6201, E6201 plus dabrafenib)

          Terminated
          Has Results
          • Malignant Melanoma
          • Brain Metastases
          • Tucson, Arizona
            University of Arizona Cancer Center
          Mar 5, 2022

          Metastatic Malignant Tumor in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 Trial in Houston (drug,

          Active, not recruiting
          • Metastatic Malignant Neoplasm in the Brain
          • +7 more
          • Houston, Texas
            M D Anderson Cancer Center
          Jun 15, 2022

          Advanced Solid Tumor, BRAF V600 Mutation Trial in Nanchang, Jinan, Shanghai (ABM-1310)

          Not yet recruiting
          • Advanced Solid Tumor
          • BRAF V600 Mutation
          • Nanchang, Jiangxi, China
          • +2 more
          Aug 12, 2022

          Tumor Skin, Metastatic Melanoma, Melanoma Trial in Orlando, Louisville (OBX-115)

          Active, not recruiting
          • Tumor Skin
          • +2 more
          • OBX-115
          • Orlando, Florida
          • +1 more
          Sep 28, 2023

          Malignant Melanoma, Metastatic Melanoma, Immunotherapy Trial (Pembrolizumab, Encorafenib, Binimetinib)

          Not yet recruiting
          • Malignant Melanoma
          • +4 more
          • (no location specified)
          Mar 31, 2022

          Cancer, BRAF V600 Mutation, Melanoma Trial (XP-102, Trametinib)

          Not yet recruiting
          • Cancer
          • +5 more
          • (no location specified)
          Aug 18, 2022

          Solid Tumors, Melanoma, NSCLC Trial in France, Spain, United States (CFT1946, Trametinib)

          Recruiting
          • Solid Tumors
          • +4 more
          • Boston, Massachusetts
          • +9 more
          Dec 19, 2022